PL366088A1 - A method for synthesizing leflunomide - Google Patents
A method for synthesizing leflunomideInfo
- Publication number
- PL366088A1 PL366088A1 PL01366088A PL36608801A PL366088A1 PL 366088 A1 PL366088 A1 PL 366088A1 PL 01366088 A PL01366088 A PL 01366088A PL 36608801 A PL36608801 A PL 36608801A PL 366088 A1 PL366088 A1 PL 366088A1
- Authority
- PL
- Poland
- Prior art keywords
- leflunomide
- trifluoromethylphenyl
- isoxazole
- carboxamide
- methyl
- Prior art date
Links
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 title abstract 6
- 229960000681 leflunomide Drugs 0.000 title abstract 6
- 230000002194 synthesizing effect Effects 0.000 title abstract 2
- SNUBGILHVSSQAY-UHFFFAOYSA-N 3-methyl-n-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 SNUBGILHVSSQAY-UHFFFAOYSA-N 0.000 abstract 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 abstract 1
- VQBXUKGMJCPBMF-UHFFFAOYSA-N 5-methyl-1,2-oxazole-4-carboxylic acid Chemical compound CC=1ON=CC=1C(O)=O VQBXUKGMJCPBMF-UHFFFAOYSA-N 0.000 abstract 1
- MIOYDAUCMWWNRH-UHFFFAOYSA-N 5-methyl-n-(4-methylphenyl)-1,2-oxazole-4-carboxamide Chemical compound O1N=CC(C(=O)NC=2C=CC(C)=CC=2)=C1C MIOYDAUCMWWNRH-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18263500P | 2000-02-15 | 2000-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL366088A1 true PL366088A1 (en) | 2005-01-24 |
Family
ID=22669359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL01366088A PL366088A1 (en) | 2000-02-15 | 2001-02-08 | A method for synthesizing leflunomide |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6723855B2 (enExample) |
| EP (1) | EP1257270B1 (enExample) |
| JP (1) | JP2004500380A (enExample) |
| KR (1) | KR20020072312A (enExample) |
| AT (1) | ATE292966T1 (enExample) |
| AU (1) | AU2001234943A1 (enExample) |
| CA (1) | CA2400290A1 (enExample) |
| CZ (1) | CZ20023024A3 (enExample) |
| DE (1) | DE60110043T2 (enExample) |
| ES (1) | ES2237553T3 (enExample) |
| HR (1) | HRP20020671A2 (enExample) |
| HU (1) | HUP0301865A3 (enExample) |
| IL (1) | IL151196A0 (enExample) |
| PL (1) | PL366088A1 (enExample) |
| SK (1) | SK12992002A3 (enExample) |
| WO (1) | WO2001060363A1 (enExample) |
| YU (1) | YU61602A (enExample) |
| ZA (1) | ZA200206494B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE207065T1 (de) * | 1997-08-08 | 2001-11-15 | Aventis Pharma Gmbh | Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid |
| HUP0204069A3 (en) * | 1999-12-16 | 2005-01-28 | Teva Pharma | Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it |
| GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| US20030139606A1 (en) * | 2001-11-09 | 2003-07-24 | Ray Anup Kumar | Process for preparing 5-methylisoxazole-4-carboxylic- (4'-trifluoromethyl)-anilide |
| RU2365373C2 (ru) * | 2003-05-27 | 2009-08-27 | Роберт Пер Хэгерквист | Применение ингибитора тирозинкиназы для лечения диабета |
| EP1694308A1 (en) * | 2003-10-30 | 2006-08-30 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
| US20060024376A1 (en) * | 2004-07-30 | 2006-02-02 | The University Of Chicago | Methods and compositions for reducing toxicity associated with leflunomide treatment |
| DE102005017592A1 (de) * | 2005-04-16 | 2006-10-19 | Lindner, Jürgen, Dr. med. | Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem |
| WO2007086076A2 (en) * | 2006-01-24 | 2007-08-02 | Unichem Laboratories Limited | An improved process for preparation of leflunomide |
| CN101817797B (zh) * | 2009-02-26 | 2013-04-10 | 江苏亚邦爱普森药业有限公司 | 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法 |
| CA2772275A1 (en) | 2009-09-18 | 2011-03-24 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| CN102002009B (zh) * | 2010-10-18 | 2012-11-07 | 齐鲁制药有限公司 | 一种5-甲基异恶唑-4-甲酰氯的制备方法 |
| US10526279B2 (en) | 2015-06-17 | 2020-01-07 | Biocon Limited | Process for the preparation of teriflunomide |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| GB8619432D0 (en) | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
| AU649421B2 (en) * | 1990-05-18 | 1994-05-26 | Sanofi-Aventis Deutschland Gmbh | Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs |
| ES2124800T3 (es) | 1993-01-08 | 1999-02-16 | Hoechst Ag | Empleo de leflunomida para la inhibicion de interleuquina 1 beta. |
| US5610173A (en) | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
| ATE207065T1 (de) * | 1997-08-08 | 2001-11-15 | Aventis Pharma Gmbh | Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid |
| DE19908527C2 (de) * | 1999-02-26 | 2001-08-30 | Aventis Pharma Gmbh | Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
| HUP0204069A3 (en) * | 1999-12-16 | 2005-01-28 | Teva Pharma | Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it |
-
2001
- 2001-02-08 EP EP01907127A patent/EP1257270B1/en not_active Expired - Lifetime
- 2001-02-08 PL PL01366088A patent/PL366088A1/xx not_active Application Discontinuation
- 2001-02-08 US US09/779,928 patent/US6723855B2/en not_active Expired - Fee Related
- 2001-02-08 WO PCT/US2001/004095 patent/WO2001060363A1/en not_active Ceased
- 2001-02-08 KR KR1020027010595A patent/KR20020072312A/ko not_active Ceased
- 2001-02-08 AT AT01907127T patent/ATE292966T1/de not_active IP Right Cessation
- 2001-02-08 HU HU0301865A patent/HUP0301865A3/hu unknown
- 2001-02-08 HR HRP20020671 patent/HRP20020671A2/hr not_active Application Discontinuation
- 2001-02-08 JP JP2001559460A patent/JP2004500380A/ja active Pending
- 2001-02-08 AU AU2001234943A patent/AU2001234943A1/en not_active Abandoned
- 2001-02-08 ES ES01907127T patent/ES2237553T3/es not_active Expired - Lifetime
- 2001-02-08 YU YU61602A patent/YU61602A/sh unknown
- 2001-02-08 DE DE60110043T patent/DE60110043T2/de not_active Expired - Fee Related
- 2001-02-08 CZ CZ20023024A patent/CZ20023024A3/cs unknown
- 2001-02-08 IL IL15119601A patent/IL151196A0/xx unknown
- 2001-02-08 SK SK1299-2002A patent/SK12992002A3/sk unknown
- 2001-02-08 CA CA002400290A patent/CA2400290A1/en not_active Abandoned
-
2002
- 2002-08-14 ZA ZA200206494A patent/ZA200206494B/en unknown
-
2003
- 2003-12-10 US US10/730,949 patent/US20040127532A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20023024A3 (cs) | 2003-05-14 |
| WO2001060363A1 (en) | 2001-08-23 |
| AU2001234943A1 (en) | 2001-08-27 |
| IL151196A0 (en) | 2003-04-10 |
| YU61602A (sh) | 2006-01-16 |
| ES2237553T3 (es) | 2005-08-01 |
| DE60110043D1 (de) | 2005-05-19 |
| HRP20020671A2 (en) | 2004-12-31 |
| CA2400290A1 (en) | 2001-08-23 |
| KR20020072312A (ko) | 2002-09-14 |
| ZA200206494B (en) | 2003-08-20 |
| DE60110043T2 (de) | 2006-03-02 |
| EP1257270A1 (en) | 2002-11-20 |
| SK12992002A3 (sk) | 2003-05-02 |
| EP1257270A4 (en) | 2003-05-07 |
| US6723855B2 (en) | 2004-04-20 |
| US20040127532A1 (en) | 2004-07-01 |
| HUP0301865A2 (hu) | 2003-09-29 |
| US20020022646A1 (en) | 2002-02-21 |
| JP2004500380A (ja) | 2004-01-08 |
| HUP0301865A3 (en) | 2005-12-28 |
| EP1257270B1 (en) | 2005-04-13 |
| ATE292966T1 (de) | 2005-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL151196A0 (en) | A method for synthesizing leflunomide | |
| MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
| NO20006645L (no) | Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme | |
| MXPA03007853A (es) | Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos. | |
| MXPA02011621A (es) | Mimeticos de trombopoyetina. | |
| UA48939C2 (uk) | Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки | |
| HUP0303128A2 (hu) | O-dezmetil-venlafaxin új szukcinátsója, eljárás az előállításukra, alkalmazása és ezt tartalmazó gyógyszerkészítmény | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| JO2216B1 (en) | 5 chloro-3 (4-methane sulfonyl phenyl) -6-methyl- (2.3) | |
| SG149045A1 (en) | Novel fused pyrrolocarbazoles | |
| MXPA04002256A (es) | Uso de gonadotropina corionica humana (gch) en hiperestimulacion ovarica controlada. | |
| MY149041A (en) | Novel fused pyrrolocarbazoles | |
| MY126117A (en) | Pharmaceutical compositions | |
| UA66792C2 (uk) | Спосіб отримання 2-арил-3-арил-5-галогенпіридинів, що використовуються як інгібітори сох-2 (варіанти) | |
| TR200503401T1 (tr) | Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları | |
| NO20061791L (no) | Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin | |
| MXPA04000446A (es) | 4-aminociclohexanoles sustituidos. | |
| MX2009003974A (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion. | |
| NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
| HRP20040086A2 (en) | Use of hcg and lh in controlled ovarian hyperstimulation | |
| IL117157A (en) | Preparation of factor ix form biological sources | |
| ATE111455T1 (de) | 3-substituierte 1,2,3,4-oxatriazol-5- iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel. | |
| AU2003267551A1 (en) | Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone | |
| ATE496038T1 (de) | Verfahren zur herstellung von quetiapin | |
| WO2004038067A3 (en) | Polyphenolamine composition and method of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |